Physician profile
Mark A Yackley
NPI 1356347215
$10,292.52
in general payments reported to CMS, 2019-2025
39 companies · $957 in 2025
The $957 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $732 · 2020: $4,807 · 2022: $1,040 · 2023: $1,402 · 2024: $1,356 · 2025: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,713.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,331.89 | 2019-2024 | |
| Novo Nordisk INC | $1,050.14 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $944.84 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $611.02 | 2022-2024 | Vraylar, Qulipta, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $238.87 | 2022-2025 | Xifaxan |
| Lilly USA, LLC | $177.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $167.62 | 2022-2025 | |
| Daiichi Sankyo INC. | $150.69 | 2019-2025 | Injectafer |
| Abbott Laboratories | $144.63 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $143.63 | 2019-2025 | |
| Astellas Pharma US INC | $138.09 | 2022-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $103.32 | 2022-2023 | Keveyis |
| Abiomed | $97.17 | 2025 | |
| Sanofi-Aventis U.S. LLC | $92.78 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $92.65 | 2023-2025 | Gemtesa |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Yackley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.